Anti-heat shock protein 10 IgG in chronic spontaneous urticaria: Relation with miRNA-101-5p and platelet-activating factor.
HSP10
Interlukin-4
anti-HSP10 antibody
degranulation
mast cells
microRNA
platelet-activating factor
urticaria
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
revised:
02
06
2023
received:
16
03
2023
accepted:
06
06
2023
medline:
4
12
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
ppublish
Résumé
Anti-heat shock protein (HSP) autoantibodies are detected in autoimmune diseases. We sought to ascertain whether anti-HSP10 IgG is present in patients with CSU and to elucidate the role of HSP10 in CSU pathogenesis. Using a human proteome microarray, six potential autoantibodies had higher expression in 10 CSU samples compared with 10 normal controls (NCs). Among them, HSP10 IgG autoantibody was quantified by immune dot-blot assay in sera from 86 CSU patients and 44 NCs. The serum levels of HSP10 and microRNA-101-5p were measured in CSU patients and NCs. The effects of HSP10 and miR-101-5p on mast cell degranulation in response to IgE, compound 48/80, and platelet-activating factor (PAF) were investigated. CSU patients had higher IgG positivity to HSP10 (40.7% vs. 11.4%, p = .001), lower serum HSP10 levels (5.8 ± 3.6 vs. 12.2 ± 6.6 pg/mL, p < .001) than in NCs, and their urticaria severity was associated with anti-HSP10 IgG positivity, while HSP10 levels were related to urticaria control status. MiR-101-5p was increased in CSU patients. PAF enhanced IL4 production in PBMCs from CSU patients. IL-4 upregulated miR-101-5p and reduced HSP10 expression in keratinocytes. Transfection of miR-101-5p reduced HSP10 expression in keratinocytes. MiR-101-5p promoted PAF-induced mast cell degranulation, while HSP10 specifically prevented it. A new autoantibody, anti-HSP10 IgG was detected in CSU patients, which showed a significant correlation with UAS7 scores. A decreased serum HSP10 level was associated with upregulation of miR-101-5p due to increased IL-4 and PAF in CSU patients. Modulation of miR-101-5p and HSP10 may be a novel therapeutic approach for CSU.
Sections du résumé
BACKGROUND
Anti-heat shock protein (HSP) autoantibodies are detected in autoimmune diseases. We sought to ascertain whether anti-HSP10 IgG is present in patients with CSU and to elucidate the role of HSP10 in CSU pathogenesis.
METHOD
Using a human proteome microarray, six potential autoantibodies had higher expression in 10 CSU samples compared with 10 normal controls (NCs). Among them, HSP10 IgG autoantibody was quantified by immune dot-blot assay in sera from 86 CSU patients and 44 NCs. The serum levels of HSP10 and microRNA-101-5p were measured in CSU patients and NCs. The effects of HSP10 and miR-101-5p on mast cell degranulation in response to IgE, compound 48/80, and platelet-activating factor (PAF) were investigated.
RESULTS
CSU patients had higher IgG positivity to HSP10 (40.7% vs. 11.4%, p = .001), lower serum HSP10 levels (5.8 ± 3.6 vs. 12.2 ± 6.6 pg/mL, p < .001) than in NCs, and their urticaria severity was associated with anti-HSP10 IgG positivity, while HSP10 levels were related to urticaria control status. MiR-101-5p was increased in CSU patients. PAF enhanced IL4 production in PBMCs from CSU patients. IL-4 upregulated miR-101-5p and reduced HSP10 expression in keratinocytes. Transfection of miR-101-5p reduced HSP10 expression in keratinocytes. MiR-101-5p promoted PAF-induced mast cell degranulation, while HSP10 specifically prevented it.
CONCLUSION
A new autoantibody, anti-HSP10 IgG was detected in CSU patients, which showed a significant correlation with UAS7 scores. A decreased serum HSP10 level was associated with upregulation of miR-101-5p due to increased IL-4 and PAF in CSU patients. Modulation of miR-101-5p and HSP10 may be a novel therapeutic approach for CSU.
Substances chimiques
MicroRNAs
0
Platelet Activating Factor
0
Interleukin-4
207137-56-2
Autoantibodies
0
Immunoglobulin G
0
MIRN101 microRNA, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3166-3177Subventions
Organisme : Korea Health Technology R&D Project
ID : HR16C0001
Organisme : National Research Foundation of Korea
ID : NRF-2018R1A2B6006199
Organisme : National Research Foundation of Korea
ID : NRF-2022R1A2C2006607
Informations de copyright
© 2023 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766.
Mostmans Y, De Smedt K, Richert B, Elieh Ali Komi D, Maurer M, Michel O. Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: a systematic review. Allergy. 2021;76(10):2998-3016.
Metz M, Altrichter S, Buttgereit T, et al. The diagnostic workup in chronic spontaneous urticaria-what to test and why. J Allergy Clin Immunol Pract. 2021;9(6):2274-2283.
Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876-882.
Schoepke N, Asero R, Ellrich A, et al. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST study. Allergy. 2019;74(12):2427-2436.
Ulambayar B, Chen YH, Ban GY, et al. Detection of circulating IgG autoantibody to FcepsilonRIalpha in sera from chronic spontaneous urticaria patients. J Microbiol Immunol Infect. 2020;53(1):141-147.
Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772-1781.e1.
Kolkhir P, Altrichter S, Asero R, et al. Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2021;13(4):545-559.
Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol. 2002;2(3):185-194.
Spierings J, van Eden W. Heat shock proteins and their immunomodulatory role in inflammatory arthritis. Rheumatology. 2017;56(2):198-208.
Ahn HR, Baek GO, Yoon MG, et al. Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma. J Exp Clin Cancer Res. 2022;41(1):158.
Kasperska-Zajac A, Damasiewicz-Bodzek A, Bieniek K, Skrzypulec-Frankel A, Tyrpien-Golder K, Grzanka A. Elevated circulating heat shock protein 70 and its antibody concentrations in chronic spontaneous urticaria. Int J Immunopathol Pharmacol. 2018;31:1-6. doi:10.1177/394632017750440
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402-408.
Luo Y, Fernandez Vallone V, He J, et al. A novel approach for studying mast cell-driven disorders: mast cells derived from induced pluripotent stem cells. J Allergy Clin Immunol. 2022;149(3):1060-1068 e4.
Seki T, Yuasa S, Fukuda K. Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nat Protoc. 2012;7(4):718-728.
Pham DL, Lim KM, Joo KM, Park HS, Leung DYM, Ye YM. Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients. Sci Rep. 2017;7(1):1318.
Bao L, Chau C, Bao J, Tsoukas MM, Chan LS. IL-4 dysregulates microRNAs involved in inflammation, angiogenesis and apoptosis in epidermal keratinocytes. Microbiol Immunol. 2018;62(11):732-736.
Kolkhir P, Gimenez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):61.
Maurer M, Eyerich K, Eyerich S, et al. Urticaria: collegium internationale allergologicum (CIA) update 2020. Int Arch Allergy Immunol. 2020;181(5):321-333.
David S, Bucchieri F, Corrao S, et al. Hsp10: anatomic distribution, functions, and involvement in human disease. Front Biosci (Elite Ed). 2013;5(2):768-778.
Jia H, Halilou AI, Hu L, Cai W, Liu J, Huang B. Heat shock protein 10 (Hsp10) in immune-related diseases: one coin, two sides. Int J Biochem Mol Biol. 2011;2(1):47-57.
Mantej J, Polasik K, Piotrowska E, Tukaj S. Autoantibodies to heat shock proteins 60, 70, and 90 in patients with rheumatoid arthritis. Cell Stress Chaperones. 2019;24(1):283-287.
Kasperkiewicz M, Tukaj S, Gembicki AJ, et al. Evidence for a role of autoantibodies to heat shock protein 60, 70, and 90 in patients with dermatitis herpetiformis. Cell Stress Chaperones. 2014;19(6):837-843.
Takizawa S, Endo T, Wanjia X, Tanaka S, Takahashi M, Kobayashi T. HSP 10 is a new autoantigen in both autoimmune pancreatitis and fulminant type 1 diabetes. Biochem Biophys Res Commun. 2009;386(1):192-196.
Lai NS, Lan JL, Yu CL, Lin RH. Antibody to mycobacterium tuberculosis 65 kDa heat shock protein in patients with rheumatoid arthritis-a survey of antigen-specific antibody isotypes and subclasses in an endemic area of previous tuberculosis infection. Ann Rheum Dis. 1995;54(3):225-228.
Athanasas-Platsis S, Zhang B, Hillyard NC, et al. Early pregnancy factor suppresses the infiltration of lymphocytes and macrophages in the spinal cord of rats during experimental autoimmune encephalomyelitis but has no effect on apoptosis. J Neurol Sci. 2003;214(1-2):27-36.
Shamaei-Tousi A, D'Aiuto F, Nibali L, et al. Differential regulation of circulating levels of molecular chaperones in patients undergoing treatment for periodontal disease. PloS ONE. 2007;2(11):e1198.
Kajiwara N, Sasaki T, Bradding P, et al. Activation of human mast cells through the platelet-activating factor receptor. J Allergy Clin Immunol. 2010;125(5):1137-1145. e6.
Belanger C, Elimam H, Lefebvre J, Borgeat P, Marleau S. Involvement of endogenous leukotriene B4 and platelet-activating factor in polymorphonuclear leucocyte recruitment to dermal inflammatory sites in rats. Immunology. 2008;124(3):295-303.
Huang YH, Schafer-Elinder L, Owman H, Lorentzen JC, Ronnelid J, Frostegard J. Induction of IL-4 by platelet-activating factor. Clin Exp Immunol. 1996;106(1):143-148.
Church MK, Kolkhir P, Metz M, Maurer M. The role and relevance of mast cells in urticaria. Immunol Rev. 2018;282(1):232-247.
Smith CH, Kepley C, Schwartz LB, Lee TH. Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol. 1995;96(3):360-364.
Nettis E, Dambra P, Loria M, et al. Mast-cell phenotype in urticaria. Allergy. 2001;56(9):915.
Upton JEM, Grunebaum E, Sussman G, Vadas P. Platelet activating factor (PAF): a mediator of inflammation. Biofactors. 2022;48(6):1189-1202.
Yoshikawa M, Matsumoto K, Iida M, Akasawa A, Moriyama H, Saito H. Effect of extracellular matrix proteins on platelet-activating factor-induced eosinophil chemotaxis. Int Arch Allergy Immunol. 2002;128(Suppl 1):3-11.
Ulambayar B, Yang EM, Cha HY, Shin YS, Park HS, Ye YM. Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study. Clin Transl Allergy. 2019;9:33.
Andrades E, Claros M, Torres JV, et al. New transcriptome and clinical findings of platelet-activating factor in chronic spontaneous urticaria: pathogenic and treatment relevance. Biofactors. 2022;48(6):1284-1294.
Caproni M, Cardinali C, Giomi B, et al. Serological detection of eotaxin, IL-4, IL-13, IFN-gamma, MIP-1alpha, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria. J Dermatol Sci. 2004;36(1):575-579.
Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol. 2002;109(4):694-700.
Wierzbicki T, Iqbal SM, Cuvelier SL, Awong G, Tibbles LA, Patel KD. IL-4 primes human endothelial cells for secondary responses to histamine. J Leukoc Biol. 2003;74(3):420-427.
Condrat CE, Thompson DC, Barbu MG, et al. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cell. 2020;9(2):276.
Teng Y, Zhang R, Yu H, et al. Altered MicroRNA expression profiles in activated mast cells following IgE-FcεRI cross-linking with antigen. Cell Physiol Biochem. 2015;35(6):2098-2110.
Al-Shaikhly T, MacDonald JW, Bammler TK, et al. Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria. Allergy. 2021;76(4):1274-1277.
Munoz-Cano R, Ainsua-Enrich E, Torres-Atencio I, et al. Effects of rupatadine on platelet- activating factor-induced human mast cell degranulation compared with desloratadine and levocetirizine (the MASPAF study). J Investig Allergol Clin Immunol. 2017;27(3):161-168.
Hide M, Suzuki T, Tanaka A, Aoki H. Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: a 12-month, multicenter, open-label clinical trial. J Dermatol Sci. 2019;94(3):339-345.
Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7(5):1659-1661.e1.
Guhl S, Babina M, Neou A, Zuberbier T, Artuc M. Mast cell lines HMC-1 and LAD2 in comparison with mature human skin mast cells-drastically reduced levels of tryptase and chymase in mast cell lines. Exp Dermatol. 2010;19(9):845-847.